#Gilead Sciences

See a “POZ on Location” video with highlights from the United States Conference on AIDS and scroll through 15 tweets from HIV advocates.

Gilead Sciences donates $1 million; Broadway Cares, The Campbell Foundation, AIDS United and NMAC add their support.

AIDS activists urge the N.Y. attorney general to investigate possible antitrust violations regarding the HIV med used as PrEP.

The Gilead Sciences funding will be carried out in partnership with the Black AIDS Institute.

PrEP use remains largely limited to white men 25 and older, meaning groups at the very highest risk of HIV are likely not benefiting.

The Food and Drug Administration recently approved a generic formulation of Gilead Sciences’ antiretroviral Truvada.

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.

The single-tablet regimen includes the experimental bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

However, Gilead Sciences, the brand-name manufacturer of Truvada, insists a generic version “will not be immediately available.”

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

Pharmaceutical giant Gilead Sciences has awarded over $22 million in grants for 12 HIV-cure-focused research projects.

About 90,000 people in the United States are taking Truvada to prevent getting HIV.